Ralstonia mannitolilytica Infections: A Systematic Review of Case Reports Unveiling Clinical Patterns and Therapeutic Insights.

Q3 Medicine
Krishnapriya Neelambaran, Hemasri Velmurugan, Sajitha Venkatesan, Pugazhenthan Thangaraju
{"title":"Ralstonia mannitolilytica Infections: A Systematic Review of Case Reports Unveiling Clinical Patterns and Therapeutic Insights.","authors":"Krishnapriya Neelambaran, Hemasri Velmurugan, Sajitha Venkatesan, Pugazhenthan Thangaraju","doi":"10.2174/0125899775287020240424071322","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Ralstonia mannitolilytica is an emerging opportunistic pathogen that has been increasingly reported in clinical settings. Despite its low pathogenicity in immunocompetent individuals, it poses a significant threat to immunocompromised patients, particularly those with underlying medical conditions or invasive medical interventions.</p><p><strong>Objectives: </strong>This study aimed to evaluate the clinical impact and management strategies based on the analysis of individual case reports on Ralstonia mannitolilytica .</p><p><strong>Methods: </strong>A comprehensive search of PubMed was conducted from inception until July 31, 2023, using the terms \"Ralstonia mannitolilytica\" and/or \"Pseudomonas thomasii\". Inclusion criteria for our systematic review included human-centered case reports of Ralstonia mannitolilytica infections, excluding case series and review articles. Data extraction followed PRISMA guidelines, including study details and patient characteristics. Case reports were systematically assessed using the JBI critical appraisal checklist, evaluating patient demographics, clinical history, diagnostic methods, interventions, post-intervention outcomes, adverse events, and lessons learned to minimize bias risk.</p><p><strong>Results: </strong>A total of 17 case reports of Ralstonia mannitolilytica infections were included in our systematic review. Studies published from 2001 to 2023 revealed diverse global contributions, with 29.41% from China. Infection origins varied, with catheter-related cases being predominant. Mortality was reported in two studies. Antibiotic sensitivity analysis showed sensitivity to third-generation cephalosporins, notably Ceftazidime. Quality appraisal revealed that all studies had a low risk of bias, ensuring the overall robustness of the case reports.</p><p><strong>Conclusion: </strong>This study emphasizes the importance of understanding Ralstonia mannitolilytica infections, given their varied clinical presentations and antibiotic responses. The study also underscores the necessity for precise identification, customized treatments, and ongoing research to manage these infections effectively.</p>","PeriodicalId":37008,"journal":{"name":"Current Drug Research Reviews","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Drug Research Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0125899775287020240424071322","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Ralstonia mannitolilytica is an emerging opportunistic pathogen that has been increasingly reported in clinical settings. Despite its low pathogenicity in immunocompetent individuals, it poses a significant threat to immunocompromised patients, particularly those with underlying medical conditions or invasive medical interventions.

Objectives: This study aimed to evaluate the clinical impact and management strategies based on the analysis of individual case reports on Ralstonia mannitolilytica .

Methods: A comprehensive search of PubMed was conducted from inception until July 31, 2023, using the terms "Ralstonia mannitolilytica" and/or "Pseudomonas thomasii". Inclusion criteria for our systematic review included human-centered case reports of Ralstonia mannitolilytica infections, excluding case series and review articles. Data extraction followed PRISMA guidelines, including study details and patient characteristics. Case reports were systematically assessed using the JBI critical appraisal checklist, evaluating patient demographics, clinical history, diagnostic methods, interventions, post-intervention outcomes, adverse events, and lessons learned to minimize bias risk.

Results: A total of 17 case reports of Ralstonia mannitolilytica infections were included in our systematic review. Studies published from 2001 to 2023 revealed diverse global contributions, with 29.41% from China. Infection origins varied, with catheter-related cases being predominant. Mortality was reported in two studies. Antibiotic sensitivity analysis showed sensitivity to third-generation cephalosporins, notably Ceftazidime. Quality appraisal revealed that all studies had a low risk of bias, ensuring the overall robustness of the case reports.

Conclusion: This study emphasizes the importance of understanding Ralstonia mannitolilytica infections, given their varied clinical presentations and antibiotic responses. The study also underscores the necessity for precise identification, customized treatments, and ongoing research to manage these infections effectively.

甘露菌感染:病例报告的系统回顾揭示了临床模式和治疗见解。
背景:甘露菌是一种新出现的机会性病原体,在临床上的报道越来越多。尽管它在免疫功能正常的个体中致病性较低,但它对免疫功能低下的患者,尤其是那些患有基础疾病或接受过侵入性医疗干预的患者构成了重大威胁:本研究旨在根据对甘露寡糖丝菌病例报告的分析,评估其临床影响和管理策略:以 "甘露醇假单胞菌 "和/或 "托马斯假单胞菌 "为关键词,对PubMed进行了全面检索,检索期从开始到2023年7月31日。系统性综述的纳入标准包括以人为中心的甘露醇假单胞菌感染病例报告,不包括系列病例和综述文章。数据提取遵循 PRISMA 指南,包括研究细节和患者特征。采用JBI关键评估清单对病例报告进行系统评估,评估内容包括患者人口统计学特征、临床病史、诊断方法、干预措施、干预后结果、不良事件和经验教训,以最大限度地降低偏倚风险:我们的系统综述共收录了17篇关于甘露寡糖丝菌感染的病例报告。从 2001 年到 2023 年发表的研究显示,全球范围内的感染情况各不相同,其中 29.41% 来自中国。感染来源各不相同,以导管相关病例为主。有两项研究报告了死亡病例。抗生素敏感性分析表明对第三代头孢菌素,尤其是头孢他啶敏感。质量评估显示,所有研究的偏倚风险较低,确保了病例报告的整体稳健性:本研究强调了了解甘露菌感染的重要性,因为其临床表现和抗生素反应各不相同。本研究还强调了精确识别、定制治疗和持续研究对有效控制这些感染的必要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current Drug Research Reviews
Current Drug Research Reviews Medicine-Psychiatry and Mental Health
CiteScore
3.70
自引率
0.00%
发文量
38
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信